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ABSTRACT
EFFECTIVENESS OF CETYLPYRIDINIUM CHLORIDE,
CHLORHEXIDINE GLUCONATE, CHLORINE DIOXIDE,
AND ESSENTIAL OILS AGAINST
F. NUCLEATUM, P. GINGIVALIS, S. MUTANS AND S. SOBRINUS–
A BIOFILM APPROACH
Kristafer L. Adkins
Results of evaluating chemotherapeutic effectiveness have focused on planktonic, twodimensional bacterial existence. Biofilms exist as three-dimensional structures which shelter
bacteria deep within. Current research is needed to evaluate the effectiveness of various
chemotherapeutics against bacteria residing inside of a biofilm. In order to do so, this study
evaluated the effectiveness of four common chemotherapeutics (cetylpyridinium chloride,
chlorhexidine gluconate, chlorine dioxide, and essential oils) against four bacteria (S. mutans,
S. sobrinus, F. nucleatum and P. gingivalis) in both planktonic and biofilm modeled culture
media. Data was obtained through the measurement of zones of inhibition (ZOI) surrounding
test discs placed on experimental plates. ZOI comparisons were made across culture media types
and between chemotherapeutics within culture plates. F. nucleatum and P. gingivalis data were
excluded from this study, because F. nucleatum was unable to be amplified while the
P. gingivalis Poloxamer F127 plate presented with an unreadable media surface.
Chemotherapeutic effectiveness across culture media for both S. mutans and S. sobrinus
produced significant differences in resultant ZOI formation. Only CHX 100% and CPC 100%
were classified as effective agents against both bacteria across both brucella blood agar and
Poloxamer F127 media.
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INTRODUCTION
This study evaluates the ability of four common chemotherapeutics to inhibit bacterial
growth of four oral bacteria on both two-dimensional and three-dimensional culture media.
Comparisons of chemotherapeutic effectiveness will be made between differing culture media
and each chemotherapeutic. This study is the first to examine chemotherapeutic effectiveness
across two-dimensional and three-dimensional culture media.

PURPOSE OF THE STUDY
The purpose of this study is to compare the ability of four common chemotherapeutics
(cetylpyridinium chloride, chlorhexidine gluconate, chlorine dioxide, and essential oils) to inhibit
bacterial growth on both two-dimensional brucella blood agar and a three-dimensional
Poloxamer F127 culture media. The bacterial species to be tested include Streptococcus mutans,
Streptococcus sobrinus, Porphymonas gingivalis and Fusobacterium nucleatum.
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STATEMENT OF THE PROBLEM
Oral chemotherapeutic effectiveness has been evaluated through the measurement of
zones of inhibition surrounding test discs on bacterial culture plates. Brucella blood agar is the
media that traditionally has been selected for bacteria growth because it provides an accurate
representation for planktonic bacterial research. However, oral chemotherapeutics used today
target bacteria that live inside of a biofilm environment. Oral biofilms have a three-dimensional
structure. The effectiveness of chemotherapeutics on bacteria within a biofilm environment
cannot be established through culturing on brucella blood agar. Therefore, this study will
evaluate the effectiveness of various oral chemotherapeutic agents against four different bacteria
on Poloxamer F127 – a model biofilm culture media.

SIGNIFICANCE OF THE PROBLEM
A review of the current literature shows no comparison of the effectiveness of
chemotherapeutics against oral bacteria across differing dimensional culture media. Traditional
microbiological testing has focused on the ability of chemotherapeutics to inhibit bacterial
growth on a two-dimensional culture media. This study will evaluate the effectiveness of four
common chemotherapeutics against four oral bacteria in both two-dimensional and threedimensional culture media.
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REVIEW OF THE LITERATURE

Personal Home Oral Health Care
Daily personal oral hygiene recommendations vary from one oral healthcare provider to
another and are tailored to the needs of the individual patient. Historically, mechanical plaque
control methods have predominated. Mechanical plaque control can be achieved primarily
through the use of toothbrushes (electric and manual) and interdental cleaning aids, such as floss,
irrigators, etcetera.
Studies have shown that mechanical plaque control alone may not result in adequate
plaque control. Researchers in the United Kingdom conducted a study in which participants’
teeth were examined for the presence of visible dental plaque. Approximately one-third of the
participants that brushed their teeth before the examination still presented with visible plaque.1
Another study conducted by Christersson et al found no participants to be completely plaque
free, and 35.7% had visible plaque on at least 90% of tooth surfaces.2
In the absence of adequate plaque control through mechanical methods, adjunctive
chemotherapeutic mouthrinses have been incorporated into the home care regimen. The concept
of inclusion of mouthrinsing into the daily home care regimen began with the use of children’s
urine in China in 2700 B.C.3 Since then, various concoctions have been used for mouthrinsing
purposes.
More recently, Barnett described the rationale for use of an effective chemotherapeutic
mouthrinse as being twofold. The first reason for incorporating an effective chemotherapeutic
into the daily oral hygiene regimen is that a chemotherapeutic may play a role in adequate plaque
control, resulting in the prevention and control of periodontal diseases. Another reason for the
daily use of an oral chemotherapeutic is that oral microbial ecology suggests that
-3-

chemotherapeutic activity in the mouth significantly impacts the bacterial colonization of the
teeth, both supragingivally and subgingivally.4
The significance of adequate plaque control in the prevention of gingival and periodontal
diseases has been well documented. Loe and colleagues have shown that plaque accumulation is
critical in the development of gingivitis.5 Additional undisturbed plaque accumulation is
accompanied by changes in the bacterial composition of the biofilm. In early biofilm formation,
Gram-positive aerobic bacteria predominate the microflora. As the biofilm ages and extends into
the gingival sulcus, its composition becomes dominated by Gram-negative anaerobic bacteria
species.6 More than 500 bacterial species exist in the oral environment.7

The Biofilm Challenge
A biofilm can be defined as a collection of bacteria living within an organized matrix
composed of extracellular polymeric substances.8,9 An important characteristic of a biofilm is
the presence of a pseudo-circulatory system in which nutrients and metabolic wastes can be
moved throughout the biofilm via fluidic movement.10
Increased antibiotic resistance has been associated with biofilm bacteria when compared
to planktonic bacteria. Biofilm bacteria are 10-1000 times less susceptible to antimicrobial
agents than are planktonic bacteria.11
There have been many proposed mechanisms thought to be responsible for this difference
in resistance. The ability of chemotherapeutics to penetrate the depth of the biofilm should be
considered. Rates of diffusion of chemotherapeutics have been proposed to be slower within the
three dimensional biofilm. The polymeric matrix of the biofilm has been shown to retard
chemotherapeutic diffusion when compared to diffusion in plain water.12
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Another proposal for biofilm bacteria’s resistance to chemotherapeutics examines the
effects of the chemotherapeutic itself on the bacteria contained within the biofilm. Within a
biofilm, not all bacteria are equal to chemotherapeutic susceptibility. Chemotherapeutics have
been shown to be less effective against bacteria that are not actively growing. Thus, the nutrient
starved bacteria are not affected in the same manner by the chemotherapeutic as are actively
growing bacteria.12
A third hypothesis proposes that bacteria develop a new protected phenotype against oral
chemotherapeutics. As the biofilm evolves, it loses its chemotherapeutic susceptibility.12
Biofilm susceptibility is an issue that needs to be addressed in oral microbiological
research. Traditional chemotherapeutic testing with associated culturing techniques has focused
using a two-dimensional culture medium, such as brucella blood agar. This technique accurately
represents qualities of planktonic bacteria. However, oral bacteria exist in a three-dimensional
biofilm structure. Differences between planktonic and biofilm bacterial growth can be explained
through the dimensions in which growth occurs. Planktonic bacterial growth is simulated
through bacterial culturing on a media in which growth is limited to the surface of the media.
Biofilm bacterial growth simulation is achieved by using a culture media in which bacterial
growth occurs both on the surface and within the culture media. Thus, the need to evaluate
chemotherapeutic effectiveness on a three-dimensional culture medium exists.13
Poloxamer F127 has been identified as a model for biofilm microbiological research.
Poloxamer F127’s structure closely mimics the three-dimensional structure of oral biofilm.
Poloxamer F127 is a di-block copolymer consisting of polyoxyethylene and polyoxypropylene.
An interesting property of Poloxamer F127 is that it exhibits thermoreversible gelation. At
temperatures below 15°C Poloxamer F127 exists as a liquid, while at temperatures above 15°C
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gelation occurs. Poloxamer F127 also possesses the ability to be autoclaved without destroying
the integrity of the media.14

Adjunctive Chemotherapeutics
Chlorine Dioxide (ClO2)
Chlorine dioxide’s disinfectant properties have been noted since the early 1900’s. In
1967, the EPA registered the liquid form of ClO2 as both a disinfectant and a sanitizer.
Currently, ClO2 is being used in food processing, water treatment, surface disinfection, and for
dental waterline cleansing.15 Recently, ClO2 has gained interest in the research community as an
oral chemotherapeutic. Chlorine dioxide’s mechanism of action includes oxidization of bacterial
cell walls which leads to the disruption of nutrient transport, resulting in the death of the
bacteria.16
The majority of research pertaining to the use of ClO2 as an oral chemotherapeutic relates
to the treatment of halitosis. The primary etiology of halitosis has been identified as the presence
of volatile sulfur compounds (VSCs), including hydrogen sulfide, methyl mercaptan, and
dimethyl sulfide. Volatile sulfur compounds are produced by the metabolic processes of oral
bacteria, such as P. gingivalis.17 Many other oral chemotherapeutics such as chlorhexidine
gluconate (CHX), cetylpyridinium chloride (CPC), and essential oils (EO) have all been
evaluated for their effectiveness in treating halitosis.18
Only one study was found that directly relates to this research. In the study, 77 patients
received an oral prophylaxis. After the prophylaxis, patients were assigned to either a CHX or a
ClO2 rinsing group. Patients were instructed for the next three days to refrain from their normal
oral hygiene regimen. Twice a day, patients were required to rinse with 10ml of the assigned
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chemotherapeutic for one minute. After three days, plaque accumulation was assessed using the
Plaque Index. The results of the study indicated that ClO2 was inferior to CHX as a plaque
inhibitor.19
Cetylpyridinium Chloride (CPC)
Cetylpyridinium chloride is classified as a quaternary ammonium compound. Quaternary
ammonium compounds have been found to inhibit bacterial growth.20 Much like ClO2 containing
oral chemotherapeutics, CPC has been used as a treatment for halitosis. A study conducted by
Kozlovsky et al compared two vehicles, one containing CPC and one without CPC, and their
ability to reduce halitosis. The CPC containing vehicle produced the greatest reduction in
halitosis.21
A study by Witt et al most closely relates CPC and an EO containing mouthrinse in
regards to effectiveness in plaque inhibition. Participants underwent two treatment phases, one
in which they were instructed to use 20ml of the assigned mouthrinse twice a day for 30 seconds.
After the treatment period of five days, participants were evaluated using the Turesky
modification of the Quigley-Hein Index. Plaque scores were recorded separately for buccal and
lingual surfaces. Participants were then instructed to switch chemotherapeutics and repeat the
oral hygiene regimen as previously prescribed. Comparison of the plaque indices for each
chemotherapeutic revealed that neither CPC nor EO chemotherapeutics was superior to the other
in inhibiting plaque accumulation.22 A study Albert-Kiszely et al also compared the plaque
accumulation inhibition abilities of CPC and EO, reinforcing the results of the Witt et al study.23
The CPC containing chemotherapeutic evaluated in this study contained CPC at a
concentration of 0.07%.
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Essential Oils (EO)
Essential oil containing oral chemotherapeutics are among the most commonly
researched mouthrinses and have been shown to be active against a broad spectrum of bacteria,
including S. mutans. In vitro, bacterial death has been noted in as little as 30 seconds after
contact with an EO chemotherapeutic.24 Essential oil chemotherapeutics, along with CHX, have
an ability to penetrate plaque biofilm, thereby increasing their effectiveness against embedded
bacteria.25-27
Of significant importance is the ability of EO and CHX chemotherapeutics to provide
substantivity beyond the rinsing period. Suppression of the oral flora is detectable for several
hours after use of an EO containing chemotherapeutic.24,28-29
Two negatives are often associated with EO containing chemotherapeutics. First, the
vehicle for delivery often contains alcohol, sometimes as high as 26.9%. Thus, these
chemotherapeutics should be used with caution, such as is in patients with xerostomia or an
alcohol dependency.30 Second, the pH of some EO containing chemotherapeutics is as low as
5.5. The significance of this pH is that a pH of 5.5 is the critical level in which tooth
demineralization can occur. Therefore, frequency and duration of each use should follow that of
the recommendations of the manufacturer.31
The essential oil chemotherapeutic evaluated in this study contained eucalyptol, menthol,
thymol and methyl salicylate as the active ingredients.
Chlorhexidine Gluconate (CHX)
Chlorhexidine gluconate, a bisbiguanide, is the most researched oral chemotherapeutic in
terms of limiting cariogenic activity and gingivitis.32 CHX kills bacteria by disrupting their cell
walls thereby damaging the cell’s cytoplasm.33 Experimental research often uses CHX as the
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“gold” standard against which the performance of other oral chemotherapeutic agents is
measured. An important consideration of CHX use is that it should not be used for extended
periods of time due to its potential for staining of the teeth and taste alteration.34 In the United
States, CHX is supplied in a concentration of 0.12%. The vehicle for delivery of CHX includes
alcohol at a concentration of 11.6%.35 Alcohol containing chemotherapeutics should be
recommended with caution as previously stated.
CHX studies span periods of time six months or longer. Plaque reductions have been
reported ranging from 16-45%, while gingivitis reductions have been reported ranging from
27-80%. Similar studies evaluating the plaque and gingivitis reduction capabilities of EO
chemotherapeutics show ranges of 22-36% and 23-36%, respectively.36
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Materials and Methods
Day 1
Using a sterile pipette, five 5mL conical vials were filled with 4mL of brain-heart
infusion (BHI) broth. Each vial was labeled according to the bacteria to be introduced for
amplification. Lids were lightly screwed onto each vial after being placed into a rack for
transport to and storage in the anaerobic chamber (Bactron 1.5 Anaerobic Chamber; 90%
nitrogen, 5% hydrogen, 5% carbon dioxide).
The rack of five BHI vials, packets containing P. gingivalis (ATCC 33277) and S. mutans
(ATCC 35668) inoculating loops, and four packets containing anaerobic brucella plates were
introduced into the anaerobic chamber. These items were left in the chamber for 24 hours to
reduce the oxygen on the surface of the materials and from within the BHI broth.
Already included in the incubator cabinet of the anaerobic chamber were blood agar
plates containing colonies of F. nucleatum and S. sobrinus, isolated from a clinical setting. The
laboratory containing the anaerobic chamber also keeps stocks of various bacteria growing to
preserve the integrity of the chamber.
Day 2
Lids to the BHI vials were removed prior to introducing bacteria into the broth of the
appropriately labeled BHI vials. A S. mutans inoculating loop was removed from its sterile
packaging. The loop tip was placed into the S. mutans labeled BHI vial. By repeatedly bending
the loop tip back and forth, the plastic loop was separated from the handle and dropped into the
BHI broth. This process was repeated for P. gingivalis. Due to the difficulty of growing
P. gingivalis, two vials were created to increase the likelihood of obtaining bacterial growth in at
least one vial.
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Both F. nucleatum and S. sobrinus were already available through stock blood agar plates
in the anaerobic chamber’s incubator. Using a sterile inoculating loop, viable colonies were
removed from the F. nucleatum blood agar plate. The loop tip was placed into the F. nucleatum
labeled BHI vial. By repeatedly bending the loop tip back and forth, the plastic loop tip was
separated from the handle and dropped into the BHI broth. This process was repeated for
S. sobrinus.
The rack of five bacteria-BHI vials were placed into the incubator of the anaerobic
chamber for a period of 48 hours to allow for bacterial growth.
Day 4
The rack containing the five bacteria-BHI vials was removed from the incubator, but not
the anaerobic chamber. Each vial was inspected for the presence of bacterial growth. The
presence of a cloudiness of the bacteria-BHI solution indicated positive bacterial growth. All
five vials tested positive for bacterial growth.
Once bacterial growth was verified, Poloxamer F127 plates were prepared. Poloxamer
F127, removed from the laboratory refrigerator, six large microbiological plates, and a graduated
cylinder were taken to a refrigerated room. Four of the large microbiological plates were labeled
with both that day’s date and the name of one of the four bacteria to be studied. Two
microbiological plates were filled with Poloxamer F127 to serve as extra plates. The extra plates
were to be used whenever the integrity of the test Poloxamer F127 plates was compromised
during bacterial streaking. Sixty milliliters of Poloxamer F127 were measured in the graduated
cylinder and then slowly poured into the large microbiological plates in an effort to eliminate the
presence of bubbles in the final media. Once all six plates were filled with Poloxamer F127, the
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plates were transferred to the incubator cabinet within the anaerobic chamber. This allowed the
Poloxamer F127 to gel prior to bacterial streaking.
While awaiting gelation of the Poloxamer F127, chemotherapeutic dilutions were created
in 8 - 250ml beakers as follows:
1) 100% CHX = CHX 100ml
2) 50% CHX = CHX 50ml + saline (NERL Blood Bank Saline – pH 7.0-7.2) 50ml
3) 100% CPC = CPC 100ml
4) 50% CPC = CPC 50ml + saline (NERL Blood Bank Saline – pH 7.0-7.2) 50ml
5) 100% EO = EO 100ml
6) 50% EO = EO 50ml + saline (NERL Blood Bank Saline – pH 7.0-7.2) 50ml
7) 100% ClO2 = ClO2 100ml
8) 50% ClO2 = ClO2 50ml + saline (NERL Blood Bank Saline – pH 7.0-7.2) 50ml
Six petri dishes were separated into tops and bottoms and labeled with the above eight
solutions, with the four remaining halves labeled Blank Control, Saline Control, Ciprofloxacin,
and Penicillin.
Blank sterile discs were loaded with chemotherapeutic solutions by capillary action
through touching the disc to the solution with a pair of forceps. It is important to note that discs
were not submerged into the chemotherapeutic solutions. Eight discs for each chemotherapeutic
solution were created and placed into the appropriately labeled half-dish. This process was
repeated for discs to be loaded with the saline control. Unexposed blank sterile discs were
placed into the Blank Control petri dish. Eight antibiotic discs of ciprofloxacin and eight
antibiotic discs of penicillin (both stock from the laboratory) were also gathered and placed into
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their respective half-dishes. All half-dishes were then transported to and placed into the
anaerobic chamber.
Inside the anaerobic chamber, blood agar plates were labeled with the date and names of
the four bacteria included in this study. A sterile inoculating loop was placed into a bacteria-BHI
vial and gently swirled between the thumb and index finger. The inoculating loop was removed
from the bacteria-BHI solution and gently streaked across the appropriately labeled blood agar
plate. This process was repeated for each of the four bacteria-BHI solutions.
The four brucella plates previously placed into the anaerobic chamber were removed
from their packaging. Each plate was labeled with the date and the name of one of the four
bacteria. Using a pipette, 1ml of bacteria-BHI solution was removed from the BHI vial and
placed onto the brucella media. Mini-hockey sticks were used to evenly spread the bacteria-BHI
solution across the brucella media. This process was repeated for each of the four bacteria-BHI
vials. Once all brucella plates were streaked, discs were placed according to Figure 1
(Appendix B). A reference mark was made on the outside edge of the brucella plate to indicate
the starting point for disc placement. Discs were placed onto the media by transporting the discs
from the labeled half petri dishes with a pair of forceps, dropping the disc into position, and
lightly tapping the disc to seat it onto the media. The brucella plates were then placed into the
incubator cabinet of the anaerobic chamber.
The six Poloxamer F127 plates were removed from the incubator cabinet and inspected
for quality of the pours. Bacteria were introduced onto the Poloxamer F127 plates in the same
manner as it was to the brucella media. However, 2ml of bacteria-BHI were needed instead of
only 1ml to ensure total coverage of the large Poloxamer F127 plate. Discs were placed onto the
Poloxamer F127 plates in the same manner as they were placed onto the brucella media. The
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Poloxamer F127 plates were placed into the incubator cabinet of the anaerobic chamber. Both
brucella and Poloxamer F127 plates were allowed to incubate for a period of 48 hours.
Day 6
All plates were removed from the incubator cabinet and the anaerobic chamber. Using
calipers, zones of inhibition (ZOI) were measured to the nearest millimeter and recorded in a raw
data chart. (Appendix B Figure 2).
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RESULTS
Four total culture plates were evaluated in this study: S. mutans on brucella, S. mutans on
Poloxamer F-127, S. sobrinus on brucella, and S. sobrinus on Poloxamer F127. The ZOI data,
measured in millimeters, were obtained from each of the four experimental plates.
Table 1 (Appendix A) summarizes the ZOIs obtained for each plate in a raw data table.
Analysis of variance (ANOVA) was conducted on the raw data. Results of the ANOVA are
presented in Table 2 (Appendix A). Analysis across the rows of Table 1 presents the total
variation for each individual test agent against itself for each of the four test plates. With
analysis resulting in a p-value <0.05 (p=0.00655), the variation among ZOIs for each test agent
across the four test plates was determined to be significant.
The first detailed comparison to be made was for variation in effectiveness for each test
agent (chemotherapeutics, controls, and antibiotics) across the two culture media for S. mutans.
Individual test discs were evaluated across differing culture media. Table 3 (Appendix A)
provides an isolation of the ZOIs obtained for these two plates from the raw data table. Table 3
was evaluated using ANOVA, the results of which are presented in Table 4 (Appendix A).
Variation in ZOIs across culture media for the same test disc resulted in a p-value <0.05
(p=0.01243). Variation in test agent effectiveness was determined to be significantly different
across culture media.
A similar comparison of the effectiveness against S. sobrinus across culture media was
made. Table 5 (Appendix A) provides an isolation of the obtained ZOI data for the two
S. sobrinus plates. This data was evaluated using ANOVA. The results of the ANOVA are
presented in Table 6 (Appendix A). With a resultant p-value <0.05 (p=0.04569), variation in test
agent effectiveness was determined to be significantly different.
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After evaluation of ZOI variation across differing culture media for each individual
bacterium, S. mutans and S. sobrinus, further analysis within chemotherapeutics across differing
culture media was conducted. This time, ANOVA was completed individually for each
bacterium excluding ZOI data for both positive and negative controls and the two antibiotic
discs.
S. mutans ZOI data for chemotherapeutics of each test concentration, excluding both
controls and both antibiotics, are presented in Table 7 (Appendix A). ANOVA results
determined that variation in ZOIs due to concentrations differences across differing culture
media was not significant at p >0.05 (p=0.77581). These results are presented in Table 8
(Appendix A).
S. sobrinus ZOI data for chemotherapeutics of each test concentration, excluding both
controls and both antibiotics, are presented in Table 9 (Appendix A). ANOVA results for this
comparison can be found in Table 10 (Appendix A). Across culture media, variation in ZOIs for
a given chemotherapeutic of the same concentration proved to be significant at p <0.05
(p=0.04913).
The next analysis conducted on each test plate was to rank chemotherapeutic
effectiveness from largest ZOI to smallest ZOI. The rank order for each individual test plate is
presented in Tables 11-14 (Appendix A). After creating the rank order tables, further analysis
was conducted to determine the actual effectiveness of each test chemotherapeutic and
concentration. Interpretation of these tables led to the classification of a chemotherapeutic and
its respective concentration as being effective or not effective. For the purposes of this study,
chemotherapeutics and their respective concentration that yielded ZOIs less than or equal to that
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of the positive control were classified as ineffective. All chemotherapeutics of a given
concentration that produced a ZOI larger than the positive control were classified as effective.
Table 11 presents the rank order of effectiveness of chemotherapeutics and their
concentrations for the S. mutans brucella blood agar experimental plate. As expected, the two
antibiotics, ciprofloxacin and penicillin, produced the largest ZOIs. Chemotherapeutics that
were classified as ineffective against S. mutans on brucella blood agar were EO 100% and
ClO2 100%. Interestingly, EO and ClO2 were the only chemotherapeutics whose 100%
concentrations were outperformed by their 50% concentrations. The most effective
chemotherapeutic was CPC 100%, while the least effective chemotherapeutic was ClO2 50%.
Table 12 presents the rank order of effectiveness of chemotherapeutics and their
concentrations for the S. mutans Poloxamer F127 experimental plate. Both antibiotics produced
the largest ZOIs for this experimental plate. Chemotherapeutics classified as ineffective
included ClO2 100%, ClO2 50%, EO 100%, EO 50% and CHX 50%. CHX 100% yielded a ZOI
equal to that of the penicillin antibiotic. The remaining two chemotherapeutics, CPC 100% and
CPC 50%, were the only other chemotherapeutics classified as effective. All chemotherapeutics
of 100% concentration were more effective than their 50% concentration counterpart, with the
exception of EO and ClO2, whose 50% and 100% concentrations were equally ineffective.
Table 13 presents the rank order of effectiveness of chemotherapeutics and their
concentrations for the S. sobrinus brucella blood agar experimental plate. Ciprofloxacin was the
most effective agent tested. However, intermediate in effectiveness to ciprofloxacin and
penicillin was ClO2 100%. No chemotherapeutic of any concentration was determined to be
ineffective, as all tested chemotherapeutics outperformed the positive control. The most
effective chemotherapeutic was determined to be ClO2 100% while the least effective
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chemotherapeutic was CHX 50%. All chemotherapeutics of 100% concentration outperformed
their 50% concentration counterpart.
Table 14 presents the rank order of effectiveness of chemotherapeutics and their
concentrations for the S. sobrinus Poloxamer F127 experimental plate. Several
chemotherapeutics were classified as ineffective including: CPC 50%, ClO2 100%, ClO2 50%,
EO 50% and penicillin. The most effective chemotherapeutic was determined to be EO 100%,
outperforming ciprofloxacin. The least effective chemotherapeutic agents were CHX 100%,
CHX 50% and CPC 100%, all yielding equal ZOIs. Chemotherapeutics of 100% concentration
outperformed their 50% concentration counterpart with the exception of CHX and ClO2, both of
which presented equal effectiveness across concentration.
After ranking chemotherapeutic effectiveness for each experimental plate, a rank value
was assigned to each test agent. Rank values were assigned on a scale of 1-12, with 1 being the
test agent that produced the largest ZOI and 12 being assigned to the test agent yielding the
smallest ZOI. Test agents that produced equal ZOIs were given a rank value that resulted from
the average of the rank orders that would have been assigned assuming the equally performing
test agents resulted in differing ZOIs. For example, agents ranked 1-5 all produced differing
ZOIs. A tie for the same rank value occurred beginning at the rank of 6 between four test agents.
Positions 6, 7, 8, and 9 would be used to determine the average rank of these agents; in this
example, 7.5 would be assigned to all four test agents. The following rank order would be
assigned beginning with the next rank based on position after the averaged total of the equally
performing test agents. In this example, the next assigned rank order would begin with 10. In
the event that another tie in performance across test agents presented, the same procedure was
used to assign an average rank value for the second set of equally performing test agents.
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With respect to S. mutans cultured on brucella blood agar, only EO 100% and ClO2 100%
were previously classified as ineffective. On the S. mutans Poloxamer F127 plate, EO 100%,
EO 50%, ClO2 100%, ClO2 50%, and CHX 50% were classified as ineffective. The only
chemotherapeutics classified as effective on both the brucella blood agar and the Poloxamer
F127 plates were CHX 100%, CPC 100%, and CPC 50%. For the brucella blood agar plate,
CPC 100% was the most effective chemotherapeutic while CHX 100% was the least effective.
When evaluating effectiveness ranks for chemotherapeutics against S. mutans on Poloxamer
F127, CHX 100% was determine to be the most effective chemotherapeutic while CPC 50% was
the least effective.
With respect to S. sobrinus cultured on brucella blood agar, no chemotherapeutics were
classified as being ineffective. However, when evaluating chemotherapeutic effectiveness when
cultured on Poloxamer F127, CPC 50%, ClO2 100%, ClO2 50% and EO 50% were classified as
ineffective. Therefore, the only agents that were determined to be effective against S. sobrinus
when cultured on each plate were CHX 100%, CHX 50%, CPC 100% and EO 100%. Evaluation
of chemotherapeutic effectiveness against S. sobrinus on brucella blood agar yielded the
following results in order of decreasing effectiveness: EO 100% followed by CPC 100%,
CHX 100% and CHX 50%. Evaluation of the chemotherapeutic effectiveness when switching to
the Poloxamer F127 determined EO 100% to be the most effective followed by CHX 100%,
CHX 50%, and then CPC 100%.
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DISCUSSION
The design of the study included testing on four bacteria (S. mutans, S. sobrinus,
P. gingivalis, and F. nucleatum). During implementation of the procedures, F. nucleatum was
unable to be amplified in the BHI broth. This prevented testing chemotherapeutic inhibitory
abilities against F. nucleatum.
Another difficulty associated with this study was the ability to culture P. gingivalis.
When beginning the study, difficulties associated with keeping P. gingivalis viable, even inside
of an anaerobic chamber, were noted by the assisting laboratory staff. Following their
suggestions, P. gingivalis was amplified in the BHI broth in duplicate vials. P. gingivalis was
streaked on a separate brucella blood agar plate. This plate was incubated during the same time
period as the test plates. P. gingivalis viability was confirmed by the growth of cultures on the
extra brucella blood agar plate. However, determination of the ZOIs on the P. gingivalis
Poloxamer F127 plates was not possible for the following chemotherapeutics: EO 100%,
EO 50%, CPC 100%, CPC 50%, and CHX 100%. Visual inspection of the plates after culturing
revealed that the integrity of the Poloxamer F127 gel was compromised during bacterial
streaking of the plate. The flaw in the Poloxamer F127 gel was not observed prior to the
bacterial incubation period. This resulted in the inability to obtain ZOIs for the aforementioned
chemotherapeutics and their test concentrations on the P. gingivalis Poloxamer F127 plate.
Culturing another test plate was not possible due to the inability to recover and/or amplify viable
P. gingivalis from the viability confirmation brucella blood agar plate. Thus, comparison of
chemotherapeutic effectiveness between the Poloxamer F127 plate and the brucella blood agar
for P. gingivalis cannot be made for all tested chemotherapeutics. Furthermore, ranking of
effectiveness of chemotherapeutics and their concentrations could not be completed for the
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P. gingivalis Poloxamer F127 plate. Thus, P. gingivalis experimental plates were also excluded
from the results of this study.
After exclusion of the F. nucleatum and P. gingivalis experimental plates, the study
results included chemotherapeutic effectiveness against S. mutans and S. sobrinus on both
brucella blood agar and Poloxamer F127.
Statistical significance was obtained for the variation in ZOIs obtained across culture
media for both S. mutans and S. sobrinus plates while including both controls and both
antibiotics. Data was further evaluated for significance in the differences between ZOIs across
culture media for both bacteria excluding the two controls and antibiotics. ANOVA results of
this exclusion yielded statistically significant differences in ZOIs only for the S. sobrinus
experimental plates. Keeping this in mind, data regarding S. sobrinus rank order of
chemotherapeutic effectiveness is expected to be more representative than that of the S. mutans
rank order data.
Chemotherapeutics tested for effectiveness against S. mutans when cultured on brucella
blood agar resulted in more agents being classified as effective than those determined as such
against S. mutans on Poloxamer F127. This trend was also observed in the classification of
chemotherapeutics as being effective or not when evaluating ZOI data across culture media for
S. sobrinus. Since Poloxamer F127 is more representative of a biofilm, this trend was expected
to be observed.
Only two chemotherapeutic agents, CHX 100% and CPC 100%, were observed as
effective for both S. mutans and S. sobrinus across tested culture media. Based on these
findings, CHX 100% and CPC 100% are the recommended chemotherapeutics for patients
exhibiting high oral S. mutans and S. sobrinus counts. Had results been obtainable for
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F. nucleatum and P. gingivalis, both of which are anaerobic bacteria, differing results for the
determination of the most effective chemotherapeutic would be expected.
Those wishing to duplicate this study must consider replication of each of the
experimental plates. In this study, only one of each bacteria/culture media combination plate
was evaluated. In order to obtain data more representative of the actual effectiveness of each
chemotherapeutic at their tested concentrations, multiple plates of the same bacteria/culture
media combinations must be included in the evaluation. By replicating experimental plates, the
problems associated with the P. gingivalis Poloxamer F127 plate in this study could be avoided.
If replication were included in this study, the entire compromised experimental plate could have
been excluded from the obtained data, allowing for interpretation of data for P. gingivalis
experimental plates. Replication would allow for a larger margin of error on the part of the
researcher with the greater likelihood of obtaining significant data.
If sufficient funding is available for researchers to replicate this study, a greater variety of
oral bacteria and chemotherapeutics should be included for evaluation. By including more oral
bacteria and chemotherapeutics, a broader understanding of the effectiveness of the selected
chemotherapeutics may be obtained. Data obtained in such research would better allow dental
health care professionals to make chemotherapeutic recommendations to their patients based on
the individual patient’s existing microflora.
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CONCLUSIONS
From the results of this study, the following conclusions can be made:


The observed effectiveness of all chemotherapeutics (chlorhexidine gluconate,
cetylpyridinium chloride, chlorine dioxide, and essential oils) against S. sobrinus may
more accurately represent oral chemotherapeutic effectiveness than that observed for
S. mutans.



Both chlorhexidine gluconate 100% and cetylpyridinium chloride 100% are effective
against S. mutans and S. sobrinus in planktonic and biofilm forms.



Chemotherapeutics found to be effective against S. mutans and S. sobrinus when cultured
on Poloxamer F127 more closely represent the microbiologic conditions within the oral
cavity.



Microbiological testing should be conducted to identify the patient’s oral bacterial
composition prior to recommending an oral chemotherapeutic.

RECOMMENDATIONS FOR FUTURE STUDIES


Repetition of the experimental plates containing each bacteria/culture media combination
should be conducted.



Additional oral chemotherapeutics should be tested for effectiveness against a broader
spectrum of bacteria on both two-dimensional and three-dimensional culture media.
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Table 1: Measured Zones of Inhibition (mm)

CHX 100%
CHX 50%
CPC 100%
CPC 50%

S. mutans –
Brucella
(mm)
13
13
16
14

S. sobrinus –
Brucella
(mm)
10
8
12
11

S. mutans –
Poloxamer
(mm)
12
7
10
9

S. sobrinus –
Poloxamer
(mm)
9
9
9
8

ClO2 100%

6

23

8

8

ClO2 50%
EO 100%
EO 50%
Negative Control
Positive Control
Ciprofloxacin
Penicillin

12
10
15
6
10
36
22

14
16
10
6
6
38
21

8
8
8
6
8
15
12

8
18
6
6
8
12
8
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Table 2: Measured ZOI: Analysis of Variance (Model)
ANOVA: Two-Factor Without
Replication
SUMMARY
CHX 100%
CHX 50%
CPC 100%
CPC 50%
ClO2 100%
ClO2 50%
EO 100%
EO 50%
Negative Control
Positive Control
Ciprofloxacin
Penicillin
S. mutans – Brucella
S. sobrinus – Brucella
S. mutans – Poloxamer F127
S. sobrinus – Poloxamer F127

Count
4
4
4
4
4
4
4
4
4
4
4
4

Sum
44
37
47
42
45
42
52
39
24
32
101
63

Average
11.00
9.25
11.75
10.50
11.25
10.50
13.00
9.75
6.00
8.00
25.25
15.75

Variance
3.33333
6.91667
9.58333
7.00000
62.25000
9.00000
22.66667
14.91667
0.00000
2.66667
186.25000
46.91667

12
12
12
12

173
175
111
109

14.41667
14.58333
9.25000
9.08333

65.17424
83.17424
6.56818
10.26515

ANOVA
Source of Variation
Rows
Columns
Error

SS
1044.16667
341.66667
772.83333

df
MS
11 94.92424
3 113.88889
33 23.41919

Total

2158.66667

47
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F
P-value
4.05327 0.00086
4.86306 0.00655

F crit
2.09325
2.89156

Table 3: Measured ZOI: Brucella vs. Poloxamer - S. mutans

CHX 100%
CHX 50%
CPC 100%
CPC 50%

S. mutans –
Brucella
(mm)
13
13
16
14

S. mutans –
Poloxamer
(mm)
12
7
10
9

ClO2 100%

6

8

ClO2 50%
EO 100%
EO 50%
Negative Control
Positive Control
Ciprofloxacin
Penicillin

12
10
15
6
10
36
22

8
8
8
6
8
15
12
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Table 4: ZOI ANOVA – Brucella vs. Poloxamer F127 – S. mutans
ANOVA: Two-Factor Without
Replication
SUMMARY
CHX 100%
CHX 50%
CPC 100%
CPC 50%
ClO2 100%
ClO2 50%
EO 100%
EO 50%
Negative Control
Positive Control
Ciprofloxacin
Penicillin
S. mutans – Brucella
S. mutans – Poloxamer F127

Count
2
2
2
2
2
2
2
2
2
2
2
2

Sum
25
20
26
23
14
20
18
23
12
18
51
34

Average
Variance
12.50
0.50000
10.00 18.00000
13.00 18.00000
11.50 12.50000
7.00
2.00000
10.00
8.00000
9.00
2.00000
11.50 24.50000
6.00
0.00000
9.00
2.00000
25.50 220.50000
17.00 50.00000

12
12

173
111

14.41667
9.25000

65.17424
6.56818

ANOVA
Source of Variation
Rows
Columns
Error

SS
591.33333
160.16667
197.83333

df
MS
11 53.75758
1 160.16667
11 17.98485

Total

949.33333

23
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F
P-value
F crit
2.98905 0.04142 2.81793
8.90564 0.01243 4.84434

Table 5: Measured ZOI: Brucella vs. Poloxamer F127 – S. sobrinus

CHX 100%
CHX 50%
CPC 100%
CPC 50%

S. sobrinus –
Brucella
(mm)
10
8
12
11

S. sobrinus –
Poloxamer
(mm)
9
9
9
8

ClO2 100%

23

8

ClO2 50%
EO 100%
EO 50%
Negative Control
Positive Control
Ciprofloxacin
Penicillin

14
16
10
6
6
38
21

8
18
6
6
8
12
8
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Table 6: ZOI ANOVA – Brucella vs. Poloxamer F127 – S. sobrinus
ANOVA: Two-Factor Without
Replication
SUMMARY
CHX 100%
CHX 50%
CPC 100%
CPC 50%
ClO2 100%
ClO2 50%
EO 100%
EO 50%
Negative Control
Positive Control
Ciprofloxacin
Penicillin
S. sobrinus – Brucella
S. sobrinus – Poloxamer F127

Count
2
2
2
2
2
2
2
2
2
2
2
2

Sum
19
17
21
19
31
22
34
16
12
14
50
29

Average
9.50
8.50
10.50
9.50
15.50
11.00
17.00
8.00
6.00
7.00
25.00
14.50

Variance
0.50000
0.50000
4.50000
4.50000
112.50000
18.00000
2.00000
8.00000
0.00000
2.00000
338.00000
84.50000

12
12

175
109

14.58333
9.08333

83.17424
10.26515

SS
634.33333
181.50000
393.50000

df
11
1
11

MS
57.66667
181.50000
35.77273

F
1.61203
5.07370

1209.33333

23

ANOVA
Source of Variation
Rows
Columns
Error
Total
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P-value
0.22050
0.04569

F crit
2.81793
4.84434

Table 7: Measured ZOI Concentration Comparison – S. mutans

S. mutans
ZOI - 100%
(mm)
13
12
16
10

S. mutans
ZOI - 50%
(mm)
13
7
14
9

ClO2 – Brucella

6

12

ClO2 - Poloxamer
EO – Brucella
EO - Poloxamer

8
10
8

8
15
8

CHX – Brucella
CHX - Poloxamer
CPC – Brucella
CPC - Poloxamer
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Table 8: ZOI ANOVA – Concentration Comparison – S. mutans
ANOVA: Two-Factor Without
Replication
SUMMARY
CHX – Brucella
CHX – Poloxamer F127
CPC – Brucella
CPC – Poloxamer F127
ClO2 – Brucella
ClO2 – Poloxamer F127
EO – Brucella
EO – Poloxamer F127
S. mutans - 100%
S. mutans - 50%

Count
2
2
2
2
2
2
2
2

Sum
26
19
30
19
18
16
25
16

Average
13.00
9.50
15.00
9.50
9.00
8.00
12.50
8.00

Variance
0.00000
12.50000
2.00000
0.50000
18.00000
0.00000
12.50000
0.00000

8
8

83
86

10.38
10.75

10.26786
9.64286

SS
94.43750
0.56250
44.93750

Df
7
1
7

MS
13.49107
0.56250
6.41964

F
2.10153
0.08762

139.93750

15

ANOVA
Source of Variation
Rows
Columns
Error
Total
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P-value
0.17414
0.77581

F crit
3.78704
5.59145

Table 9: Measured ZOI Concentration Comparison – S. sobrinus
S. sobrinus
ZOI - 100%
(mm)
10
9
16
8

S. sobrinus
ZOI - 50%
(mm)
8
9
14
8

ClO2 - Brucella

23

14

ClO2 – Poloxamer F127
EO - Brucella
EO – Poloxamer F127

8
16
18

8
10
6

CHX - Brucella
CHX – Poloxamer F127
CPC - Brucella
CPC – Poloxamer F127
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Table 10: ZOI ANOVA - Concentration Comparison – S .sobrinus
ANOVA: Two-Factor Without
Replication
SUMMARY
CHX – Brucella
CHX – Poloxamer F127
CPC – Brucella
CPC – Poloxamer F127
ClO2 – Brucella
ClO2 – Poloxamer F127
EO – Brucella
EO – Poloxamer F127

2
2
2
2
2
2
2
2

Sum
18
18
30
16
37
16
26
24

Average
9.00
9.00
15.00
8.00
18.50
8.00
13.00
12.00

Variance
2.00000
0.00000
2.00000
0.00000
40.50000
0.00000
18.00000
72.00000

8
8

108
77

13.50
9.63

30.85714
8.55357

Rows
Columns
Error

SS
201.43750
60.06250
74.43750

Df
7
1
7

MS
28.77679
60.06250
10.63393

F
2.70613
5.64819

Total

335.93750

15

S. sobrinus - 100%
S. sobrinus - 50%

Count

ANOVA
Source of Variation
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P-value
F crit
0.10621 3.78704
0.04913 5.59145

Table 11: ZOI Rank Order S. mutans on Brucella Blood Agar
S. mutans –
Brucella
(mm)

Chemo. Rank
Value

Ciprofloxacin

36

1

Penicillin
CPC 100%
EO 50%

22
16
15

2
3
4

CPC 50%

14

5

CHX 100%

13

6.5

CHX 50%

13

6.5

ClO2 50%
EO 100%
Positive Control

12
10
10

8
9.5
9.5

ClO2 100%
Negative Control

6
6

11.5
11.5
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Table 12: ZOI Rank Order S. mutans on Poloxamer F127
S. mutans –
Poloxamer
(mm)

Chemo. Rank
Value

Ciprofloxacin

15

1

CHX 100%
Penicillin
CPC 100%

12
12
10

2.5
2.5
4

CPC 50%

9

5

ClO2 100%

8

8

ClO2 50%

8

8

EO 100%
EO 50%
Positive Control

8
8
8

8
8
8

CHX 50%
Negative Control

7
6

11
12
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Table 13: ZOI Rank Order S. sobrinus on Brucella Blood Agar
S. sobrinus –
Brucella
(mm)

Chemo.
Rank Value

Ciprofloxacin

38

1

ClO2 100%
Penicillin
EO 100%

23
21
16

2
3
4

ClO2 50%

14

5

CPC 100%

12

6

CPC 50%

11

7

CHX 100%
EO 50%
CHX 50%

10
10
8

8.5
8.5
10

Negative Control
Positive Control

6
6

11.5
11.5
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Table 14: ZOI Rank Order S. sobrinus on Poloxamer F127
S. sobrinus –
Poloxamer
(mm)

Chemo. Rank
Value

EO 100%

18

1

Ciprofloxacin
CHX 100%
CHX 50%

12
9
9

2
4
4

CPC 100%

9

4

CPC 50%

8

8

ClO2 100%

8

8

ClO2 50%
Positive Control
Penicillin

8
8
8

8
8
8

EO 50%
Negative Control

6
6

11.5
11.5
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APPENDIX B
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Figure 1 - Experimental Plate Layout
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Figure 2
Zone of Inhibition Chart
Bacteria: ________________________________________
Culture Media:

45
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Dental Hygiene Thesis, August 2007 - Current
Streptococcus Mutans Accumulation on Athletic Mouthguards,
West Virginia University Undergraduate Research Project,
August 2005 – February 2007

LICENSURE

West Virginia State Dental Hygiene License, July 2007 – Current
West Virginia State Dental Hygiene General Supervision License,
July 2010 - Current
Pennsylvania State Dental Hygiene License, July 2007 – Current

MEMBERSHIP

West Virginia University School of Dentistry Alumni Association,
2007 – Current
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Student American Dental Hygienists’ Association (SADHA),
August 2003 – May 2007
Student American Dental Hygienists’ Association (SADHA),
Chapter President, August 2006 - May 2007

COURSES
TAUGHT
(STUDENT
TEACHING)

CONTINUING
EDUCATION
COURSES
ATTENDED

Dental Hygiene Teaching Methods - DH 378 – 2 credits
(January 2008 – May 2008)
Clinical Dental Hygiene 2 – DH 374 – 3 credits
(January 2008 – May 2008)
Clinical Dental Hygiene 1 – DH 372 – 2 credits
(August 2007 – December 2007)
Interdisciplinary Approach to Public Health – DH 380 – 1 credit
(August 2006 – December 2006)
Dental Hygiene Techniques – DH 225 – 4 credits
(January 2006 – May 2006)

West Virginia University School of Dentistry, “Perio-Esthetics: The Use
of Gene-Based Testing to Enhance Esthetic Outcomes and Create
Healthier Patients”, September 24, 2010, Morgantown, West Virginia,
7 hours
West Virginia University School of Dentistry, “Emergency Medicine in
Dentistry”, April 24, 2010, Morgantown, West Virginia, 7 hours
West Virginia University School of Dentistry, “How to Achieve Success
Dentally, Personally, and Professionally”, September 25, 2009,
Morgantown, West Virginia, 7 hours
West Virginia University School of Dentistry, “Cosmetic Dentistry: The
Pursuit of Excellence”, November 7, 2008, Morgantown, West Virginia,
7 hours
West Virginia University School of Dentistry, “School of Dentistry
Infection Control CBL Module 2007”, October 18, 2007, Morgantown,
West Virginia, 1.5 hours
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West Virginia University School of Dentistry, “Contemporary
Bondodontics”, October 12, 2007, Morgantown, West Virginia, 7 hours
West Virginia University School of Dentistry, “13th Annual Drs Paul &
Laura Mesaros Lecture”, October 11, 2007, Morgantown, West Virginia,
2 hours
CONTINUING
EDUCATION
COURSES
ONLINE

Proctor and Gamble, “Diseases of the Teeth and Jaws”, May 26, 2010,
4 hours
Proctor and Gamble, “Guidelines for Infection Control in Dental HealthCare Settings”, May 26, 2010, 4 hours
Proctor and Gamble, “Antibacterial and Antiplaque Effects of an
Alcohol-Free Oral Rinse with Cetylpyridinium Chloride (CPC)”,
May 11, 2010, 1 hour
Proctor and Gamble, “Biofilm: A New View of Plaque”, May 11, 2010,
2 hours
ProBusiness Online, “A Guide to Sports Dentistry”, January 29, 2010,
1 hour
ProBusiness Online, “Drop the Shield and Attract More Patients”,
January 29, 2010, 1 hour
ProBusiness Online, “Latex Allergy: Critical Issues, Management
Protocols and Product Choices”, January 29, 2010, 1 hour
DenTrek, “Everyday Dentistry – Much More than Everday Esthetic
Results with Composite Resin”, January 29, 2010, 1 hour
DenTrek, “Excellence and Predictibility Creating Esthetic Restorations”,
January 29, 2010, 1 hour
GSC Home Study Courses, “Introduction to Forensic Dentistry – Basic
Principles and Legal Implications”, January 27, 2010, 3 hours
PennWell, “Periodontal Disease: Etiology, Classification and Treatment:
A Team Approach”, January 27, 2010, 1 hour
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PennWell, “Restorative Factors: Inducing Periodontal Complications”,
January 27, 2010, 1 hour
PennWell, “The Art and Science of Non-Surgical Periodontal Treatment
Planning”, July 11, 2008, 1 hour
PennWell, “Periodontal Disease and Perio/Systemic Links”, July 11, 2008,
1 hour
PennWell, “The Art and Science of Effective Communication for NonSurgical Periodontal Treatment”, July 11, 2008, 1 hour
PennWell, “Bacterial Origins of Periodontal Disease”, July 11, 2008,
1 hour
SERVICE

Tutored students in dental radiography, West Virginia University School
of Dentistry, August 2007 – December 2007
Student Research Assistant, “Wear of Coated Orthodontic Wires”, Lead
Researcher Dr. Michael Bagby, West Virginia University School of
Dentistry, Morgantown, West Virginia {funded by W.L. Gore &
Associates (Elkton, Maryland)}
Created lecture PowerPoint CD for: Marcia Gladwin & Michael Bagby.
“Clinical Aspects of Dental Materials: Theory, Practice, and Cases. 3rd
ed.” Lippincott, Williams & Wilkins, Baltimore, MD, 2009.
Created lecture PowerPoint CD for Dr. Marcia Gladwin’s DH 360: Dental
Materials course, March 2008
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